Roche buy the rights to drug that’s meant to switch on genes blocking growth of cancer

17th April 2014

The purchase gives Roche its first drug in human testing in the field of epigenetics. Roche will pay Oryzon $21 million up front and for meeting near-term targets, plus payments that may exceed $500 million if the drug meets other goals.

Roche agreed to buy the rights from Spain’s Orvzon Genomics to an experimental drug that’s meant to switch on genes that block the growth of cancer, a new area in the crowded field of potential oncology therapies.Roche will pay Oryzon $21 million up front and for meeting near-term targets, plus payments that may exceed $500 million if the drug meets other goals.

 

Read more at source article: www.irishtimes.com


Leave a Reply

Your email address will not be published.

5 + 2 =

« back to posts